array:19 [
  "pii" => "X0211699502027881"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2002-04-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2002;22 Supl 2:12"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1532
    "formatos" => array:3 [
      "EPUB" => 181
      "HTML" => 1026
      "PDF" => 325
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699502027873"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2002-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2002;22 Supl 2:13"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2437
      "formatos" => array:3 [
        "EPUB" => 195
        "HTML" => 1935
        "PDF" => 307
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Large artery damage and hypertension in end-stage renal failure (ESRD)"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "13"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "G. M. LONDON"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "G. M. LONDON"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027873?idApp=UINPBA000064"
    "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027873/v0_201502091327/en/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X021169950202789X"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2002-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2002;22 Supl 2:10-1"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2688
      "formatos" => array:3 [
        "EPUB" => 195
        "HTML" => 2140
        "PDF" => 353
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Endoglina, un componente del complejo de receptores de TGF-b, es un regulador de la estructura y función vascular"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "10"
          "paginaFinal" => "11"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J. V. RIVAS , F. PÉREZ-BARRIOCANAL , J. M. LÓPEZ NOVOA , A. RODRIGUEZ-BARBERO , M. JERKIC , R. CARRÓN , M. A. SEVILLA , C. BERNABÉU"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J. V. RIVAS , F. PÉREZ-BARRIOCANAL , J. M. LÓPEZ NOVOA , A. RODRIGUEZ-BARBERO , M. JERKIC , R. CARRÓN , M. A. SEVILLA , C. BERNABÉU"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X021169950202789X?idApp=UINPBA000064"
    "url" => "/02116995/00000022000000S2/v0_201502091327/X021169950202789X/v0_201502091327/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Effects of AT1 blockade on myocardial fibrosis in hypertensive heart disease. Beyond the control of blood pressure"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "12"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "J. DÍEZ"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "J. DÍEZ"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XXII. Suplemento 2. 2002 Effects of AT1 blockade on myocardial fibrosis in hypertensive heart disease. Beyond the control of blood pressure J. Díez University Clinic and School of Medicine. University of Navarra. Pamplona. Spain. An exaggerated accumulation of fibrillar collagens type I and type III occurs throughout the free wall and interventricular septum of animals and humans with arterial hypertension 1. A rise in collagen content has been shown to raise myocardial stiffness and promote abnormalities of cardiac function that predispose to heart failure 2. A number of previous experimental findings suggest that direct fibroblast stimulation by angiotensin II may be involved in myocardial fibrosis associated with arterial hypertension 3. Furthermore, we have shown recently that AT1 blockade with losartan at doses that do not normalize blood pressure regress myocardial fibrosis in rats with spontaneous hypertension 4, 5. Thus, in a recent study 6 we have investigated whether chronic blockade of AT1 receptors reverses myocardial fibrosis in patients with essential hypertension beyond the hemodynamic effect. The study was performed in 37 patients with essential hypertension in which ischemic cardiomyopathy was excluded after a complete medical work-up. After randomization, 21 patients were treated with losartan 50 mg/day and 16 patients received the calcium channel blocker amlodipine (2.5-10 mg/d) as treatment. At baseline and after 12 months, right septal endomyocardial biopsies were performed to quantify myocardial collagen content. Collagen volume fraction (CVF) was determined on picrosirius red-stained sections using an automated image analysis system. The serum concentration of carboxy-terminal propeptide of procollagen type I (PIP), a marker of collagen type I synthesis and deposition at the myocardial level 7, was measured by specific RIA. Time-course changes in blood pressure and final values of blood pressure were similar in the two groups of patients In patients treated with losartan, CVF decreased from 5.65 ± 0.47 to 3.96 ± 0.34% (M ± SEM, P < 0.01) and PIP from 127 ± 7 to 99 ± 6 µg/L (P < 0.01). Neither CVF nor PIP changed significantly in patients treated with amlodipine. A direct correlation was found between CVF and serum PIP (r = 0.44, P < 0.001) in all hypertensives before and after treatment. Losartan-treated patients, but nor amlodipine-treated patients exhibited an amelioration of Doppler parameters assessing end-diastolic left ventricular distensibility. These findings suggest that the ability of antihypertensive drugs to regress myocardial fibrosis in hypertensives is beyond its antihypertensive efficacy. In addition, our results suggest that angiotensin II antagonism is associated with inhibition of collagen type I synthesis, regression of myocardial fibrosis and improvement of diastolic function in hypertensive patients. Thus, the cardioreparative ability of losartan may be beneficial in hypertensive heart disease and other cardiac diseases evolving to heart failure via myocardial fibrosis. REFERENCES 1. 2. 3. 4. 5. 6. 7. Weber KT. Curr Opin Cardiol 15: 264-272, 2000. Weber KT, Brilla CG. Circulation 83: 1849-1865, 1991. Weber KT. Regul Pept 82: 1-17, 1999. Varo N y cols.: J Hypertens 17: 107-114, 1999. Varo N y cols.: Hypertension 35: 1197-1202, 2000. López B y cols.: Circulation 104: 286-291, 2001. Querejeta R y cols.: Circulation 101: 1729-1735, 2000. 12 "
    "pdfFichero" => "P7-E193-S140-A3593.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027881/v0_201502091327/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000022000000S2/v0_201502091327/X0211699502027881/v0_201502091327/en/P7-E193-S140-A3593.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027881?idApp=UINPBA000064"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Effects of AT1 blockade on myocardial fibrosis in hypertensive heart disease. Beyond the control of blood pressure
J. DÍEZ
Leído
3991
Veces
se ha leído el artículo
1729
Total PDF
2262
Total HTML
Compartir estadísticas
 array:19 [
  "pii" => "X0211699502027881"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2002-04-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2002;22 Supl 2:12"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1532
    "formatos" => array:3 [
      "EPUB" => 181
      "HTML" => 1026
      "PDF" => 325
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699502027873"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2002-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2002;22 Supl 2:13"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2437
      "formatos" => array:3 [
        "EPUB" => 195
        "HTML" => 1935
        "PDF" => 307
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Large artery damage and hypertension in end-stage renal failure (ESRD)"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "13"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "G. M. LONDON"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "G. M. LONDON"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027873?idApp=UINPBA000064"
    "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027873/v0_201502091327/en/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X021169950202789X"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2002-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2002;22 Supl 2:10-1"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2688
      "formatos" => array:3 [
        "EPUB" => 195
        "HTML" => 2140
        "PDF" => 353
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Endoglina, un componente del complejo de receptores de TGF-b, es un regulador de la estructura y función vascular"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "10"
          "paginaFinal" => "11"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J. V. RIVAS , F. PÉREZ-BARRIOCANAL , J. M. LÓPEZ NOVOA , A. RODRIGUEZ-BARBERO , M. JERKIC , R. CARRÓN , M. A. SEVILLA , C. BERNABÉU"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J. V. RIVAS , F. PÉREZ-BARRIOCANAL , J. M. LÓPEZ NOVOA , A. RODRIGUEZ-BARBERO , M. JERKIC , R. CARRÓN , M. A. SEVILLA , C. BERNABÉU"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X021169950202789X?idApp=UINPBA000064"
    "url" => "/02116995/00000022000000S2/v0_201502091327/X021169950202789X/v0_201502091327/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Effects of AT1 blockade on myocardial fibrosis in hypertensive heart disease. Beyond the control of blood pressure"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "12"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "J. DÍEZ"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "J. DÍEZ"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XXII. Suplemento 2. 2002 Effects of AT1 blockade on myocardial fibrosis in hypertensive heart disease. Beyond the control of blood pressure J. Díez University Clinic and School of Medicine. University of Navarra. Pamplona. Spain. An exaggerated accumulation of fibrillar collagens type I and type III occurs throughout the free wall and interventricular septum of animals and humans with arterial hypertension 1. A rise in collagen content has been shown to raise myocardial stiffness and promote abnormalities of cardiac function that predispose to heart failure 2. A number of previous experimental findings suggest that direct fibroblast stimulation by angiotensin II may be involved in myocardial fibrosis associated with arterial hypertension 3. Furthermore, we have shown recently that AT1 blockade with losartan at doses that do not normalize blood pressure regress myocardial fibrosis in rats with spontaneous hypertension 4, 5. Thus, in a recent study 6 we have investigated whether chronic blockade of AT1 receptors reverses myocardial fibrosis in patients with essential hypertension beyond the hemodynamic effect. The study was performed in 37 patients with essential hypertension in which ischemic cardiomyopathy was excluded after a complete medical work-up. After randomization, 21 patients were treated with losartan 50 mg/day and 16 patients received the calcium channel blocker amlodipine (2.5-10 mg/d) as treatment. At baseline and after 12 months, right septal endomyocardial biopsies were performed to quantify myocardial collagen content. Collagen volume fraction (CVF) was determined on picrosirius red-stained sections using an automated image analysis system. The serum concentration of carboxy-terminal propeptide of procollagen type I (PIP), a marker of collagen type I synthesis and deposition at the myocardial level 7, was measured by specific RIA. Time-course changes in blood pressure and final values of blood pressure were similar in the two groups of patients In patients treated with losartan, CVF decreased from 5.65 ± 0.47 to 3.96 ± 0.34% (M ± SEM, P < 0.01) and PIP from 127 ± 7 to 99 ± 6 µg/L (P < 0.01). Neither CVF nor PIP changed significantly in patients treated with amlodipine. A direct correlation was found between CVF and serum PIP (r = 0.44, P < 0.001) in all hypertensives before and after treatment. Losartan-treated patients, but nor amlodipine-treated patients exhibited an amelioration of Doppler parameters assessing end-diastolic left ventricular distensibility. These findings suggest that the ability of antihypertensive drugs to regress myocardial fibrosis in hypertensives is beyond its antihypertensive efficacy. In addition, our results suggest that angiotensin II antagonism is associated with inhibition of collagen type I synthesis, regression of myocardial fibrosis and improvement of diastolic function in hypertensive patients. Thus, the cardioreparative ability of losartan may be beneficial in hypertensive heart disease and other cardiac diseases evolving to heart failure via myocardial fibrosis. REFERENCES 1. 2. 3. 4. 5. 6. 7. Weber KT. Curr Opin Cardiol 15: 264-272, 2000. Weber KT, Brilla CG. Circulation 83: 1849-1865, 1991. Weber KT. Regul Pept 82: 1-17, 1999. Varo N y cols.: J Hypertens 17: 107-114, 1999. Varo N y cols.: Hypertension 35: 1197-1202, 2000. López B y cols.: Circulation 104: 286-291, 2001. Querejeta R y cols.: Circulation 101: 1729-1735, 2000. 12 "
    "pdfFichero" => "P7-E193-S140-A3593.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027881/v0_201502091327/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000022000000S2/v0_201502091327/X0211699502027881/v0_201502091327/en/P7-E193-S140-A3593.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027881?idApp=UINPBA000064"
]
Información del artículo
ISSN: 02116995
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 5 10 15
2024 Octubre 33 37 70
2024 Septiembre 25 24 49
2024 Agosto 48 40 88
2024 Julio 29 31 60
2024 Junio 34 35 69
2024 Mayo 32 26 58
2024 Abril 26 25 51
2024 Marzo 23 19 42
2024 Febrero 28 45 73
2024 Enero 19 28 47
2023 Diciembre 15 27 42
2023 Noviembre 26 30 56
2023 Octubre 39 31 70
2023 Septiembre 24 21 45
2023 Agosto 20 19 39
2023 Julio 23 26 49
2023 Junio 26 14 40
2023 Mayo 26 34 60
2023 Abril 14 13 27
2023 Marzo 12 15 27
2023 Febrero 16 22 38
2023 Enero 23 18 41
2022 Diciembre 21 25 46
2022 Noviembre 22 21 43
2022 Octubre 31 41 72
2022 Septiembre 20 21 41
2022 Agosto 25 44 69
2022 Julio 26 35 61
2022 Junio 15 28 43
2022 Mayo 23 27 50
2022 Abril 26 28 54
2022 Marzo 20 32 52
2022 Febrero 28 28 56
2022 Enero 23 24 47
2021 Diciembre 24 36 60
2021 Noviembre 18 27 45
2021 Octubre 25 41 66
2021 Septiembre 18 29 47
2021 Agosto 22 31 53
2021 Julio 21 35 56
2021 Junio 10 18 28
2021 Mayo 21 27 48
2021 Abril 36 42 78
2021 Marzo 18 14 32
2021 Febrero 21 11 32
2021 Enero 10 24 34
2020 Diciembre 12 12 24
2020 Noviembre 12 14 26
2020 Octubre 9 6 15
2020 Septiembre 13 6 19
2020 Agosto 13 14 27
2020 Julio 12 8 20
2020 Junio 18 15 33
2020 Mayo 17 16 33
2020 Abril 18 12 30
2020 Marzo 10 15 25
2020 Febrero 24 16 40
2020 Enero 23 19 42
2019 Diciembre 11 14 25
2019 Noviembre 11 11 22
2019 Octubre 11 8 19
2019 Septiembre 15 9 24
2019 Agosto 8 9 17
2019 Julio 18 10 28
2019 Junio 6 6 12
2019 Mayo 6 6 12
2019 Abril 26 24 50
2019 Marzo 14 10 24
2019 Febrero 3 11 14
2019 Enero 5 13 18
2018 Diciembre 16 13 29
2018 Noviembre 28 13 41
2018 Octubre 19 11 30
2018 Septiembre 18 14 32
2018 Agosto 14 8 22
2018 Julio 11 6 17
2018 Junio 13 8 21
2018 Mayo 10 8 18
2018 Abril 18 2 20
2018 Marzo 11 4 15
2018 Febrero 8 4 12
2018 Enero 8 3 11
2017 Diciembre 13 8 21
2017 Noviembre 7 3 10
2017 Octubre 13 3 16
2017 Septiembre 6 7 13
2017 Agosto 14 3 17
2017 Julio 14 6 20
2017 Junio 14 3 17
2017 Mayo 15 4 19
2017 Abril 10 2 12
2017 Marzo 10 3 13
2017 Febrero 14 1 15
2017 Enero 13 3 16
2016 Diciembre 12 5 17
2016 Noviembre 23 3 26
2016 Octubre 37 7 44
2016 Septiembre 28 3 31
2016 Agosto 71 3 74
2016 Julio 63 5 68
2016 Junio 45 0 45
2016 Mayo 63 0 63
2016 Abril 16 0 16
2016 Marzo 12 0 12
2016 Febrero 20 0 20
2016 Enero 16 0 16
2015 Diciembre 16 0 16
2015 Noviembre 15 0 15
2015 Octubre 23 0 23
2015 Septiembre 32 0 32
2015 Agosto 11 0 11
2015 Julio 18 0 18
2015 Junio 1 0 1
2015 Mayo 18 0 18
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Nefrología